2 YEARS OF EXPERIENCE
2 YEARS OF EXPERIENCE

For postmenopausal women
with a recent osteoporotic fracture:
Help change the course of
postmenopausal osteoporosis
at 18 months with TYMLOS4

TYMLOS, an anabolic agent for postmenopausal osteoporosis, demonstrated4,5:

  • 86% relative risk reduction (RRR) in new vertebral fractures vs placebo (P<0.0001) and 3.6% absolute risk reduction (ARR) at 18 months4
  • 43%RRR in nonvertebral fractures vs placebo (P=0.049)
    and 2.0% ARR at 19 months4†

Data current as of March 2020.1,3

Data included 18 months of treatment plus 1 month without treatment; P value
based on the log-rank test.4

Download resources to help patients get access to TYMLOS treatment

Download Now

Learn about efficacy results that were maintained with sequential therapy

Learn More

Watch the abaloparatide mechanism of action video

Watch Now

References: 1. Data on file. Radius Health, Inc; Waltham, MA. 2. Data on file. Radius Health, Inc; Waltham, MA. 3. Data on file. Radius Health, Inc; Waltham, MA. 4. TYMLOS® [prescribing information]. Waltham, MA: Radius Health, Inc; 2018. 5. Moreira CA, Fitzpatrick LA, Wang Y, Recker RR. Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial. Bone. 2017;97:314-317.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2020 Radius Health, Inc.   All rights reserved.    04/20.   TYM-US-03380

This site is intended for HCPs in the United States.
TYMLOS is a registered trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2020 Radius Health, Inc.
All rights reserved. 04/20.
TYM-US-03380

Back to Top